Synergistic Inhibition of Tumor Growth by MET and COX-2 Targeting in Gastric and Colorectal Cancers

Scientists developed AspMet, a dual MET/COX-2 inhibitor that suppresses gastric and colorectal cancer growth by blocking oncogenic signaling, epithelial–mesenchymal transition, and angiogenesis.